Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Read Moreby John Pinching | Sep 9, 2022 | News | 0
Research showed significant improvements in signs and symptoms of prurigo nodularis
Read Moreby John Pinching | Sep 5, 2022 | News | 0
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
Read Moreby John Pinching | Jul 14, 2022 | News | 0
Trial focusing on children with eosinophilic oesophagitis has met its primary endpoint
Read Moreby Lucy Parsons | Oct 22, 2021 | News | 0
Dupixent significantly reduced itch and skin lesions compared to placebo in the investigational trial setting
Read Moreby Lucy Parsons | Aug 31, 2021 | News | 0
Sanofi/Regeneron biologic offers alternative to topical steroids
Read Moreby Lucy Parsons | May 18, 2021 | News | 0
Detailed results found Dupixent improved overall asthma control in children aged six to 11 years old
Read Moreby Lucy Parsons | Mar 5, 2021 | News | 0
Sanofi is also planning an EU regulatory submission for Dupixent in the same indication
Read Moreby Lucy Parsons | Nov 30, 2020 | News | 0
First biologic to be approved for children aged six to 11 years with condition
Read Moreby Lucy Parsons | Oct 13, 2020 | News | 0
Biologic therapy hit primary and all key secondary endpoints in phase III
Read Moreby Selina McKee | Apr 3, 2020 | News | 0
Nearly three times as many children achieved clear or almost clear skin when treated with Dupixent and standard-of-care topical corticosteroids
Read Moreby Anna Smith | Aug 6, 2019 | News | 0
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
Read Moreby Anna Smith | Jun 28, 2019 | News | 0
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
